COOL-LAMPS. VII. Quantifying Strong-lens Scaling Relations with 177 Cluster-scale Gravitational Lenses in DECaLS

We compute parametric measurements of the Einstein-radius-enclosed total mass for 177 cluster-scale strong gravitational lenses identified by the ChicagO Optically-selected Lenses Located At the Margins of Public Surveys (COOL-LAMPS) collaboration with lens redshifts ranging from $0.2 \lessapprox z \lessapprox 1.0$ using only two measured parameters in each lensing system: the Einstein radius, and the brightest-cluster-galaxy (BCG) redshift. We then constrain the Einstein-radius-enclosed luminosity and stellar mass by fitting parametric spectral energy distributions (SEDs) with aperture photometry from the Dark Energy Camera Legacy Survey (DECaLS) in the $g$, $r$, and $z$-band Dark Energy Camera (DECam) filters. We find that the BCG redshift, enclosed total mass, and enclosed luminosity are strongly correlated and well described by a planar relationship in 3D space. We also find that the enclosed total mass and stellar mass are correlated with a logarithmic slope of $0.443\pm0.035$, and the enclosed total mass and stellar-to-total mass fraction are correlated with a logarithmic slope of $-0.563\pm0.035$. The correlations described here can be used to validate strong lensing candidates in upcoming imaging surveys -- such as Rubin/Legacy Survey of Space and Time (LSST) -- in which an algorithmic treatment of lensing systems will be needed due to the sheer volume of data these surveys will produce.Comment: 17 pages, 5 figures, 2 tables. Submitted to The Astrophysical Journal. v3: updated authors, formatting, grammar, and reference

Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study

Abstract Sorafenib therapy improves overall survival (OS) in patients with FLT3 internal tandem duplication (ITD) acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation. We explored the efficacy of sorafenib therapy in this population with different concomitant genetic patterns. In this multi-center, cohort study, we enrolled patients with FLT3-ITD AML undergoing allogenic hematopoietic cell transplantation. Patients with sorafenib maintenance post-transplantation for at least four weeks were allocated to the sorafenib group, and otherwise to the control group. Endpoints were OS, disease-free survival, and relapse for the whole cohort and OS for genetic pattern subgroups. Among 613 patients enrolled, 275 were in the sorafenib and 338 the control group. Median follow-up was 36.5 (interquartile range (IQR), 25.2–44.7) months post-transplantation. The 3-year OS post-transplantation was 79.6% (95% confidential interval (CI) 74.8%–84.6%) and 65.2% (95% CI 60.3%–70.6%) (Hazard ratio (HR) 0.50, 95% CI 0.37–0.69; P < 0.0001) in both groups. Sorafenib maintenance post-transplantation improved OS in the favorable (HR 0.33, 95% CI 0.14–0.77; P = 0.011) and adverse (HR 0.56, 95% CI 0.33–0.93; P = 0.026) ELN 2017 risk subgroups. Patients with mutated NPM1, DNMT3A, co-occurring NPM1/DNMT3A, “activated signaling” and “DNA methylation” genes benefited in OS from sorafenib maintenance, while those carrying CEBPA, “tumor suppressors” and “myeloid transcription factors” genes did not. Patients with FLT3-ITDhigh and FLT3-ITDlow AML both benefited in OS from sorafenib maintenance. Our results identify the response of genetic patterns to sorafenib maintenance, providing new viewpoints for the optimal use of sorafenib in FLT3-ITD AML in the transplantation setting